Sun Pharmaceutical Industries Limited — Important, 23-05-2025: General Updates

Sun Pharma has announced a board meeting to approve the financial results for the quarter and half-year. It invested $25 Mn in US-based Pharmazz Inc., raising its stake to ~22.7%. Pharmazz’s drug candidates Sovateltide (stroke) and Centhaquine (hypovolemic shock) are approved in India and entering global Phase-3 trials. The deal gives Sun Pharma rights to negotiate licenses in developed markets, boosting its specialty portfolio and growth potential internationally.